This content is machine translated GLP-1 agonists continue to gain ground Semaglutide in patients with obesity and heart failure It has long been known that the active ingredient class of glucagon-like peptide-1 agonists (GLP-1) reduces cardiovascular consequences in diabetics and leads to significant weight loss in patients with obesity.…
